TIDMRENE
RNS Number : 9328P
ReNeuron Group plc
15 February 2023
ReNeuron Group plc
("ReNeuron" or "the Company" or "the Group")
Grant of Options
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell
derived exosome technologies , announces that grants were made on
14 February 2023 for options over 4,030,000 Ordinary Shares of 1p
each ("Options") under the terms of the Company's Long Term
Incentive Plan ("The Plan") and its Non-Executive Share Option
Scheme. The grants of 3,000,000 Options made to Directors and
Persons Discharging Managerial Responsibilities (PDMRs) are set out
further in the table below.
1,615,000 of the Options granted under The Plan have an exercise
price of 10.25 pence per share, this being the closing mid-market
price of the Company's shares on 14 February 2023. The Options vest
in equal proportions at 12, 24 and 36 months from the date of
grant. These Options will be exercisable if the share price of the
Company's shares exceeds 31.5p for any single period of at least 30
consecutive days.
The remaining 1,415,000 of the Options granted under The Plan
have an exercise price of 31.5 pence per share. The Options vest in
equal proportions at 12, 24 and 36 months from the date of grant.
None of these Options are subject to any further performance
conditions.
The 1,000,000 Options granted to Iain Ross are granted under the
Non-Executive Share Option Scheme. 750,000 of the Options are
granted with an exercise price of 10.25 pence per share, this being
the closing mid-market price of the Company's shares on 14 February
2023. These Options will be exercisable if the share price of the
Company's shares exceeds 31.5p for any single period of at least 30
consecutive days. 250,000 of the Options are granted with an
exercise price of 50.0 pence per share without any further
performance conditions. All of Mr Ross's options vest monthly over
three years on a straight-line basis.
Name Title Date of grant Number Total shares Percentage
of Options of Options over which of issued
granted options shares under
are held option
(post award)
14 February
Iain Ross Executive Chairman 2023 1,000,000 1,500,000 2.62%
-------------------- --------------- ------------ -------------- --------------
Chief Financial 14 February
John Hawkins Officer 2023 500,000 840,000 1.47%
-------------------- --------------- ------------ -------------- --------------
Chief Scientific 14 February
Randolph Corteling Officer 2023 500,000 1,000,000 1.75%
-------------------- --------------- ------------ -------------- --------------
Chief Business 14 February
Simon Dew Officer 2023 600,000 600,000 1.05%
-------------------- --------------- ------------ -------------- --------------
Chief Operations 14 February
Suzanne Hancock Officer 2023 400,000 749,326 1.31%
-------------------- --------------- ------------ -------------- --------------
S
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3100 2000
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804
654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived,
exosome-based, drug delivery platform with customisable cellular
targeting capabilities for the delivery of complex drug
modalities.
Through the generation of several unique and scalable exosome
producer cell lines, our CustomEX(TM) platform can be optimised for
specific tissues targets and payloads leading to improvements in
therapeutic outcome and a reduction in off-target effects. ReNeuron
offers a delivery mechanism for a variety of payloads such as
siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform, the Company can make allogeneic tissue cells of choice
and has the potential to produce exosomes with tissue specific
targeting ability.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to grant of share options to Directors
and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Iain Ross
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Executive Chairman
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 1,000,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 F e bruary 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Hawkins
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 500,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 February 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Randolph Corteling
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 500,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 February 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Simon Dew
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Business Officer
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 600,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 F ebruary 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Suzanne Hancock
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Head of Operations
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 400,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 February 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKZLFFXLLZBBD
(END) Dow Jones Newswires
February 15, 2023 02:00 ET (07:00 GMT)
Reneuron (AQSE:RENE.GB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Reneuron (AQSE:RENE.GB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024